Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics

Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics

The first Mydecine Speaker Series event will feature Mydecine Scientific Advisory Board Members Dr. Robin Carhart-Harris and Dr. Ruth Lanius, Chief Medical Officer Rakesh Jetly and Chief Scientific Officer Robert Roscow
Moderated by Yeji Lee, Business Insider reporter, the panelists will discuss the impact of cutting edge research in mainstream medical interest about unlocking the potential of psychedelic therapiesRobert Roscow, Chief Science Officer of Mydecine to be named to Mydecine Board of DirectorsDENVER, Dec. 10, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced today that the Company has partnered with Microdose Psychedelic Insights (“Microdose”), a leader in B2B psychedelic intelligence, to present a free, three-part live video discussion series titled “Mydecine Speaker Series” covering Research, Psychedelic Therapies, PTSD, Microdosing, and Drug Discovery.Details and schedule of the first event are as follows:
CBJ Newsmakers

Recommended
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients2020 - Year in Review